Showing 521 - 540 results of 19,550 for search '(( significant ((a decrease) OR (teer decrease)) ) OR ( significantly increased decrease ))', query time: 0.45s Refine Results
  1. 521

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  2. 522

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  3. 523

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  4. 524
  5. 525
  6. 526
  7. 527
  8. 528
  9. 529

    Fig 10 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  10. 530

    Fig 4 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  11. 531

    Fig 9 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  12. 532

    Fig 6 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  13. 533

    Fig 7 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  14. 534

    Fig 8 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  15. 535
  16. 536
  17. 537
  18. 538
  19. 539
  20. 540